Drug Repurposing for Retinoblastoma: Recent Advances

Curr Top Med Chem. 2019;19(17):1535-1544. doi: 10.2174/1568026619666190119152706.

Abstract

Retinoblastoma is the intraocular malignancy that occurs during early childhood. The current standard of care includes chemotherapy followed by focal consolidative therapies, and enucleation. Unfortunately, these are associated with many side and late effects. New drugs and/or drug combinations need to be developed for safe and effective treatment. This compelling need stimulated efforts to explore drug repurposing for retinoblastoma. While conventional drug development is a lengthy and expensive process, drug repurposing is a faster, alternate approach, where an existing drug, not meant for treating cancer, can be repurposed to treat retinoblastoma. The present article reviews various attempts to test drugs approved for different purposes such as calcium channels blockers, non-steroidal antiinflammatory drugs, cardenolides, antidiabetic, antibiotics and antimalarial for treating retinoblastoma. It also discusses other promising candidates that could be explored for repurposing for retinoblastoma.

Keywords: Antibiotics; Antidiabetics; Antimalarials; Calcium channel blockers; Cardenolides; Drug repurposing; NSAIDs; Retinoblastoma..

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antimalarials / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Calcium Channel Blockers / therapeutic use
  • Cardenolides / therapeutic use
  • Drug Repositioning*
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Retinal Neoplasms / drug therapy*
  • Retinoblastoma / drug therapy*

Substances

  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antimalarials
  • Antineoplastic Agents
  • Calcium Channel Blockers
  • Cardenolides
  • Hypoglycemic Agents